Drugs / Clover SCB-2019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05470803 | Aug → Dec 2022 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clover SCB-2019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470803 ↗ |
| Known as | SCB-2019-Clover | “Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019-Clover)” NCT05470803 ↗ |
| Modality | Vaccine | “Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019-Clover)” NCT05470803 ↗ |